Skip to main content
OpenTrials
Completed

NCT Number: NCT03372122

Removal of Bacterial Spores in Adults on Skin

The aim of this study is to compare the effectiveness of removal of spores and dirt from the skin using a single cloth bath against a cloth bath with extra rinse step, to establish whether the extra rinse stage will lead to the removal of a higher level of spores and dirt.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Bioscience Laboratories, Inc

Bozeman, Montana, 59718, United States

About this study

The purpose of this study is to evaluate and compare the ability of two test materials to remove Clostridium difficile (ATCC #700057) spores with a tripartite soil load from subjects' forearms. For this study, removal of Clostridium difficile and the associated organic soil load will be used as an indicator of potential removal efficacy for difficult-to-remove microorganisms and associated organic matter from human skin.

All test materials are currently marketed products

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects can be of either sex, 18 to 65 years of age, and of any race.
  • Subjects must be able to read and understand English.
  • Subjects must possess both forearms.
  • Subjects must have healthy and short (< 1 mm in length) fingernails and cuticles with no defects. Subjects must also have no nail extensions, artificial nails, or nail polish and must not be wearing any jewelry that cannot be removed from the hands/forearms prior to testing.
  • Subjects must have no tattoos, active skin rashes, dermatoses, or breaks in the skin of the hands or forearms. Subjects must also have no inflammatory skin conditions, such as atopic dermatitis / eczema or psoriasis, anywhere on the body.
  • Subjects must be in good general health and have no medical diagnosis of a physical condition, such as a current or recent severe illness, medicated or uncontrolled diabetes, hepatitis B, hepatitis C, an organ transplant, a heart murmur, mitral valve prolapse with heart murmur, fibromyalgia, ulcerative colitis, Crohn's disease, moderate/severe asthma requiring daily use of medication, an immunocompromised condition such as AIDS (or HIV positive), lupus, or medicated multiple sclerosis.
  • Subjects must read and sign the Informed Consent Form, Authorization to Use and Disclose Protected Health Information Form, and List of Restricted Products prior to participating in the study.

Exclusion criteria

  • Participation in a clinical study within 7 days of signing the informed consent for this study or current participation in another clinical study.
  • Known allergies or sensitivities to latex (natural rubber), alcohols, sunscreens, deodorants, laundry detergents, inks, metals, topically-applied fragrances, cleansers, soaps, lotions, or to common antibacterial agents particularly chlorhexidine gluconate.
  • Have experienced hives (raised welts) as a reaction to anything that contacted the skin.
  • Use of systemic or topical antibiotic medications during either the 7-day pre-test period or on the test day.
  • Use of systemic or topical steroids, other than for contraception, hormone therapy, or post-menopausal indications, during the 7-day pre-test period or on the test day. This includes steroid medications used to treat asthma.
  • Have an Implanon/Nexplanon or any other dermal-implanted birth control device.
  • Any prosthetic device or joint (e.g., pins, screws, plates, rods, or dental implants) anywhere in the body.
  • Any type of indwelling port (or portacath) or Peripherally Inserted Central Catheter (PICC).
  • Subject is pregnant, plans to become pregnant or impregnate a sexual partner within the pre-test and test periods of the study, or is nursing a child.
  • Subject must not be responsible for diapering, care of wounds, intravenous management, or other bed-ridden-related care roles: have any responsibility for care of children under age 3: or be living with an immunocompromised individual.
  • Any medical condition or use of any medications that, in the opinion of the Principal Investigator or consulting physician, should preclude participation.

Treatment and study plan

Chlorhexidine gluconate

Drug

A cloth to cleanse and disinfect the skin

HUBS with Hibiclens

Combination Product

A dry cloth to be used in combination with water and antimicrobial soap to cleanse and disinfect the skin

Primary outcomes

  1. Removal of Clostridium difficile and the associated organic soil load will be used as an indicator of potential removal efficacy for difficult-to-remove microorganisms and associated organic matter from human skin

    Time frame: 2 hours

    As a measure of the ability of the test materials to remove spores from the skin, reductions will be calculated by subtracting the population of spores recovered from a treated sites from the population recovered from the baseline sites.

Sponsors and collaborators

Lead sponsor

Caroline Scott

Industry

Registry information

Official study title

Evaluation of the Ability of Two Products to Remove Bacterial Spores From Subjects' Forearms

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Dec 13, 2017
Registry last updated
Mar 13, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.